Abiopharma

🔍 BURNETT JOSEPH (Executive)

Company: ClearPoint Neuro, Inc. (CLPT)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 20,000 shares of Common Stock at $2.5 per share (Direct)
  Date: 2026-01-09 | Code: M | equity_swap_involved: false | shares_owned_after: 31,565.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 20,000 shares of Common Stock at $16.12 per share (Direct)
  Date: 2026-01-09 | Code: S | equity_swap_involved: false | shares_owned_after: 11,565.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-09 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 217,059.00 | Footnotes: F3
• Sold 20,000 shares of Stock Options (right to buy) at $2.5 per share (Derivative)
  Date: 2026-01-09 | Code: M | Expires: 2027-11-07 | equity_swap_involved: false | shares_owned_after: 330,000.00 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 11, 2025 in accordance with Rule 10b5-1.
• F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $15.88 to $16.43. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
• F4: The shares subject to this option vest as follows: (i) one-third of the total shares on the first anniversary of the grant date; and (ii) the remaining two-thirds of the total shares ratably on a quarterly basis over the 2-year period immediately following the first anniversary of the grant date. The grant date is November 7, 2017.